圣地亚哥 - Viking Therapeutics, Inc. (NASDAQ: VKTX)过去一年股价上涨了令人印象深刻的114%，该公司已经启动了VK2735的二期临床试验，这是一种旨在治疗肥胖症和相关代谢疾病的口服药物。根据 InvestingPro ...

周四，Truist Securities重申了对Viking Therapeutics (NASDAQ:VKTX)股票的买入评级和120.00美元的目标价。这一积极立场源于竞争对手数据未达预期，增强了对Viking的VK2735治疗的信心。

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

JPMorgan keeps an Overweight rating and $80 price target on Viking Therapeutics (VKTX) after the company announced that it ...